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We thus believe that the minor differences between the
Trim24ex4/ and Trim24ex1/ mouse models are more likely
accounted for by differences in genetic backgrounds of the mice
and the ages at which gene expression was analyzed rather than
the existence of Trim24 isoforms arising from the Trim24ex4/
allele that were overlooked in our previous studies and for which
we ﬁnd no evidence.
Conﬂict of interest
The authors who have taken part in this letter to the editor
declared that they do not have anything to disclose regarding
funding or conﬂict of interest with respect to this manuscript.
References
[1] Khetchoumian K, Teletin M, Tisserand J, Mark M, Herquel B, Ignat M, et al.
Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic
acid receptor alpha. Nat Genet 2007;39:1500–1506.
[2] Herquel B, Ouararhni K, Khetchoumian K, Ignat M, Teletin M, Mark M, et al.
Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form
regulatory complexes that suppress murine hepatocellular carcinoma. Proc
Natl Acad Sci U S A 2011;108:8212–8217.
[3] Tisserand J, Khetchoumian K, Thibault C, Dembele D, Chambon P, Losson R.
Tripartite motif 24 (Trim24/Tif1alpha) tumor suppressor protein is a novel
negative regulator of interferon (IFN)/signal transducers and activators of
transcription (STAT) signaling pathway acting through retinoic acid receptor
alpha (Raralpha) inhibition. J Biol Chem 2011;286:33369–33379.
[4] Herquel B, Ouararhni K, Martianov I, Le Gras S, Ye T, Keime C, et al. Trim24-
repressed VL30 retrotransposons regulate gene expression by producing
noncoding RNA. Nat Struct Mol Biol 2013;20:339–346.
[5] Jiang S, Minter LC, Stratton SA, Yang P, Abbas HA, Akdemir ZC, et al. TRIM24
suppresses development of spontaneous hepatic lipid accumulation and
hepatocellular carcinoma in mice. J Hepatol 2015;62(2):371–379. http://
dx.doi.org/10.1016/j.jhep.2014.09.026.
[6] Alpern D, Langer D, Ballester B, Le Gras S, Romier C, Mengus G, et al. TAF4, a
subunit of transcription factor II D, directs promoter occupancy of nuclear
receptor HNF4A during post-natal hepatocyte differentiation. eLife
2014;3:e03613.
[7] Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2:
accurate alignment of transcriptomes in the presence of insertions, deletions
and gene fusions. Genome Biol 2013;14:R36.
Benjamin Herquel
Max Planck Institute of Immunology and Epigenetics, Stubeweg 51,
79100 Freiburg im Breisgau, Germany
Céline Keime
Irwin Davidson⇑
Institut de Génétique et de Biologie Moléculaire et Cellulaire,
1 rue Laurent Fries, 67404 Illkirch-Graffenstaden, France⇑Corresponding author.
E-mail address: irwin@igbmc.fr
JOURNAL OF HEPATOLOGY
Open access unCoagulation and ﬁbrosis: A potential non-negligible
target of statins in chronic hepatitisTo the Editor:
We read with interest the paper by Simon and colleagues demon-
strating a reduced rate of ﬁbrosis progression in HCV positive
patients receiving a chronic treatment with statins [1]. This
observation could be clinically relevant in a scenario where we
have not effective antiﬁbrotic drugs. It emerges alongside the
growing agreement on the safety of statins in patients with liver
disease, including cirrhosis [2]. Statins inhibit 3-hydroxy-3-
methyl-glutaryl-CoA (HMG-CoA) reductase and interfere with
the ‘‘mevalonate pathway’’. As a result, they exert a complex
modulation of anti-inﬂammatory and anti-proliferative proper-
ties of the endothelium. This also occurs at sinusoidal level where
endothelial cells regulate the activation of hepatic stellate cells
(HSCs) toward a myo-ﬁbroblast phenotype [3]. The clinical
results of Simon stimulated us to speculate on the mechanisms
behind the antiﬁbrotic effect of statins in chronic liver disease
along with their ability to preserve the endothelial function.
Among the pleiotropic effects of statins, their anti-inﬂamma-
tory properties have often been considered potentially useful in
chronic liver diseases [4]. However, Simon unexpectedly showed
that in his series statins reduced the rate of ﬁbrosis indepen-
dently from the reduction of the inﬂammatory activity index.
As a consequence, the authors suggested that the effect of statins
on liver histology was due to the ability of this class of drugs to
improve the endothelial function rather than to reduce
inﬂammation. In line with this hypothesis, Maieron et al. demon-
strated that liver ﬁbrosis at different stages of chronic HCV infec-
tion correlates with the plasma levels of von Willebrand factor
(vWF), a marker of endothelial dysfunction involved in hemosta-
sis [5]. Interestingly, some clinical studies observed that statins
may reduce the plasma levels of vWF (Table 1). Unfortunately,
the study by Simon et al. did not include the dosage of vWF, an
assessment that would have been useful to conﬁrm any interre-
lationships between endothelial dysfunction and ﬁbrosis pro-
gression. In our opinion, the complex interaction between
endothelium and HSCs could also be affected by the impairment
of the coagulation function in patients with liver disease as sug-
gested by different experimental observations [6]. First, thrombin
per se can activate HSCs via PAR-1 and PAR-4 (protease-activated
receptor) receptors promoting a myo-ﬁbroblast phenotype.
Second, the occurrence of micro-thrombi in small hepatic and
portal venules can lead to sinusoidal ischemic injury and hepato-
cyte apoptosis, as proposed by the ‘‘parenchymal extinction the-
ory’’. Third, antiﬁbrotic effects have been obtained by
anticoagulation in animal models and humans, with encouraging
results. Statins can interfere with several of the mentioned mech-
anisms. First, they can decrease the expression of tissue factor,
reducing thrombin formation [7]. Second, they can increase
endothelial expression of thrombomodulin that converts throm-
bin into an anticoagulant enzyme through the activation ofJournal of Hepatology 2015 vol. 63 j 276–288 277
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Table 1. Clinical studies observed that statins may reduce the plasma levels of von Willebrand factor (vWF).
Reference Type of 
study
Treatments Time of 
treatment
Number 
of patients 
(pathology)
VWF pre 
treatment (%)
VWF post 
treatment (%)
Krysiak, 2010 OS Simvastatin 20 mg/day 90 days 28 (IGT) 145.2 ± 9.7 104.2 ± 8.6
28 (IH) 147.1 ± 10.1 103.1 ± 8.7
Controls 28 (IH) 110.2 ± 8.3 106.4 ± 9.6
Joukhadar, 2000 RCT Atorvastatin 10 mg/simvastatin 
40 mg/pravastatin 40 mg
90 days 99 (IH) 124 ± 35 111 ± 40
Krysiak, 2011 RCT Simvastatin 40 mg/day 90 days 24 (IH) 147.6 ± 11.2 106.0 ± 6.5
Placebo 24 (IH) 145.3 ± 10.7 147.3 ± 9.1
RCT, randomized controlled study; OS, observational study; IGT, impaired glucose tolerance; IH, isolated hypercholesterolemia.
Letters to the Editorprotein C anticoagulant system [7]. Third, plasma from patients
treated with statins have a reduced ability to generate thrombin
as demonstrated by Tripodi et al. in 51 patients suffering from
hypercholesterolemia [8]. Interestingly, patients with non-alco-
holic fatty liver disease, the liver expression of the metabolic syn-
drome, show a procoagulant imbalance when compared with
healthy subjects [9]. Noteworthy, in this study, Simon included a
signiﬁcant proportion of patients with histologically proven
steatosis. Therefore, a positive effect of statins on a procoagulant
imbalance can be postulated also for most of the patients in this
study.
In conclusion, coagulation can play a key role in the hepatic
process of ﬁbrogenesis as well as inﬂammation and necrosis. In
this context, the statins’ ability to modulate the coagulation cas-
cade and the interplay between endothelium and HSCs could jus-
tify a signiﬁcant antiﬁbrotic effect. Accordingly, future studies
should deﬁne more precisely the statins effects on coagulation
in patients with chronic liver disease. We hope that statins, if
not a remedy of all seasons [10], will represent a spring in the
ﬁeld of antiﬁbrotic drugs.
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